Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications

Cytokine

Volumn 26, Issue 3, 2004, Pages 114-121

  Yang, B ^a   Houlberg, K ^b   Millward, A ^a   Demaine, A ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

CC chemokine receptor 2; CC chemokine receptor 5; CCR2; CCR5; Chemokines and chemokine receptors; Diabetic microvascular complications; Gene polymorphisms; MCP 1; monocyte chemotactic protein 1; RANTES; T1DM; Type 1 diabetes mellitus

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2B; CHEMOKINE RECEPTOR CCR5; MONOCYTE CHEMOTACTIC PROTEIN 1; RESTRICTION ENDONUCLEASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE;

ADOLESCENT; ADULT; CHEMOKINE CCL2; CHEMOKINES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE;

EID: 2342477769     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2004.01.005     Document Type: Article

References (69)

1. Xia Y., Pauza M.E., Feng L., Lo D. RelB regulation of chemokine expression modulates local inflammation. Am J Pathol. 151:1997;375-387
2. Ward S.G., Bacon K., Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity. 9:1998;1-11
3. Baggiolini M., Dewald B., Moser B. Human chemokines: an update. Ann Rev Immunol. 15:1997;675-705
4. Vaddi K., Keller M., Newton R.C. The chemokine facts book. 1996;Academic Press, San Diego
5. Lloyd C.M., Minto A.W., Dorf M.E., Proudfoot A., Wells T.N., Salant D.J., et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med. 185:1997;1371-1380
6. Ogata H., Takeya M., Yoshimura T., Takagi K., Takahashi K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol. 182:1997;106-114
7. Keane M.P., Standiford T.J., Strieter R.M. Chemokines are important cytokines in the pathogenesis of interstitial lung disease. Eur Respir J. 10:1997;1199-1202
8. Furuta T., Saito T., Ootaka T., Soma J., Obara K., Abe K., et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis. 21:1993;465-480
9. Young B.A., Johnson R.J., Alpers C.E., Eng E., Gordon K., Floege J., et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int. 47:1995;935-944
10. Ihm C.G., Park J.K., Hong S.P., Lee T.W., Cho B.S., Kim M.J., et al. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron. 79:1998;33-37
11. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58:2000;684-690
12. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 human-cultured mesangial cells. J Biol Chem. 277:2002;20309-20315
13. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 58:2000;1492-1499
14. Chiarelli F., Cipollone F., Mohn A., Marini M., Iezzi A., Fazia M., et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in Type 1 diabetes. Diabetes Care. 25:2002;1829-1834
15. Abu El-Asrar A.-M., Van Damme J., Put W., Veckeneer M., Dralands L., Billiau A., et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol. 123:1997;599-606
16. Capeans C., De Rojas M.V., Lojo S., Salorio M.S. C-C chemokines in the vitreous of patients with proliferative vitreorectinopathy and proliferative diabetic retinopathy. Retina. 18:1998;546-550
17. Mitamura Y., Takeuchi S., Matsuda A., Tagawa Y., Mizue Y., Nishihira J. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica. 215:2001;415-418
18. Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol. 121:2000;437-443
19. Anders H.J., Vielhauer V., Kretzler M., Cohen C.D., Segerer S., Luckow B., et al. Chemokine and chemokine receptor expression during initiation and resolution of immune complex glomerulonephritis. J Am Soc Nephrol. 12:2001;919-931
20. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 273:1996;1856-1862
21. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today. 20:1999;254-257
22. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:1996;722-725
23. Kostrikis L., Huang Y., Moore J.P., Wolinsky S.M., Zhang L., Guo Y., et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med. 4:1998;350-353
24. Huang Y., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L., He T., et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 2:1996;1240-1243
25. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:1996;367-377
26. Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., Lomb D.A., et al. Contrasting genetic influence of CCR2 and CCR5 variant on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 277:1997;959-965
27. McDermott D.H., Zimmerman P.A., Guignard F., Kleeberger C.A., Leitman S.F., Murphy P.M. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet. 352:1998;866-870
28. Barcellos L.F., Schito A.M., Rimmler J.B., Vittinghoff E., Shih A., Lincoln R., et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics. 51:2000;281-288
29. Petŕek M., Drabek J., Kolek V., Zlamal J., Welsh K.I., Bunce M., et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 162:2000;1000-1003
30. Rovin B.H., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 259:1999;344-348
31. Nakajima K., Tanaka Y., Nomiyama T., Ogihara T., Piao L., Sakai K., et al. Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes. 51:2002;238-242
32. Nakajima K., Tanaka Y., Nomiyama T., Ogihara T., Ikeda F., Kanno R., et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care. 26:2003;892-898
33. Magierowska M., Lepage V., Boubnova L., Carcassi C., de Juan D., Djoulah S., et al. Distribution of the CCR5 gene 32 base pair deletion and SDF-3′A variant in healthy individuals from different populations. Immunogenetics. 48:1998;417-419
34. Rovin B.H., Rumancik M., Tan L., Dickerson J. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest. 71:1994;536-542
35. Saitoh A., Sekizuka K., Hayashi T., Kaneko S., Suzuki Y., Tomino Y. Detection of urinary MCP-1 in patients with diabetic nephropathy. Nephron. 80:1998;99. [letter]
36. Nishioka H., Kanauchi M., Dohi K. Role of monocyte chemotactic peptide 1 in diabetic nephropathy. Nephron. 18:2001;189-190
37. Kim H.L., Lee D.S., Yang S.H., Lim C.S., Chung J.H., Kim S., et al. The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis. 40:2002;1146-1152
38. Ueda A., Okuda K., Ohno S., Shirai A., Igarashi T., Matsunaga K., et al. NF-κB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol. 153:1994;2052-2063
39. Ueda A., Ishigatsubo Y., Okubo T., Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene: cooperation of two NF-κB sites and NF-κB/Rel subunit specificity. J Biol Chem. 272:1997;31092-31099
40. Kutlu B., Darville M.I., Cardozo A.K., Eizirik D.L. Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic β-cells. Diabetes. 52:2003;348-355
41. Piemonti L., Leone B.E., Nano R., Saccani A., Monti P., Maffi P., et al. Human pancreatic islets produce and secret MCP-1/CCL2: relevance in human islet transplantation. Diabetes. 51:2002;55-65
42. Appels B., Burkart V., Kantwerk-Funke G., Funda J., Kolb-Bachofen V., Kolb H. Spontaneous cytotoxicity of macrophages against pancreatic islet cells. J Immunol. 142:1989;3803-3808
43. Shimada A., Takei I., Maruyama T., Kasuga A., Kasatani T., Watanabe K., et al. Acceleration of diabetes in young NOD mice with peritoneal macrophages. Diabetes Res Clin Pract. 24:1994;69-76
44. Cameron M.J., Arreaza G.A., Grattan M., Meagher C., Sharif S., Burdick M.D., et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type 1 diabetes. J Immunol. 165:2000;1102-1110
45. Shanmugam N., Reddy M.A., Guha M., Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 52:2003;1256-1264
46. Martin T., Cardarelli P.M., Parry G.C., Felts K.A., Cobb R.R. Cytokine induction of monocytes chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-κB and AP-1. Eur J Immunol. 27:1997;1091-1097
47. Takaishi H., Taniguchi T., Takahashi A., Ishikawa Y., Yokoyama M. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res Commun. 305:2003;122-128
48. Ruiz-Ortega M., Lorenzo O., Egido J. Angiotensin III increases MCP-1 and activates NF-κB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int. 57:2000;2285-2298
49. Wong T.Y., Phillips A.O., Witowski J., Topley N. Glucose-induced induction of TGF-β1 and MCP-1 in mesothelial cells in vitro is osmolarity and polyol pathway dependent. Kidney Int. 63:2003;1404-1416
50. Kato S., Luyckx V.A., Ots M., Lee K.W., Ziai F., Troy J.L., et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int. 56:1999;1037-1048
51. Ruiz-Ortega M., Bustos C., Hernandez-Presa M.A., Lorenzo O., Plaza J.J., Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κB activation and monocyte chemoattractant protein-1 synthesis. J Immunol. 161:1998;430-439
52. Hwang S.Y., Cho M.L., Park B., Kim J.Y., Kim Y.H., Min D.J., et al. Allelic frequency of the MCP-1 promoter -2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult-onset Still's disease. Eur J Immunogenet. 29:2002;413-416
53. Aguilar F., Gonzalez-Escribano M.F., Sanchez-Roman J., Nunez-Roldan A. MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens. 58:2001;335-338
54. Szalai C., Kozma G.T., Nagy A., Bojszko A., Krikovszky D., Szabo T., et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol. 108:2001;375-381
55. Szalai C., Duba J., Prohaszka Z., Kalina A., Szabo T., Nagy B., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis. 158:2001;233-239
56. Szalai C., Csaszar A., Czinner A., Szabo T., Panczel P., Madacsy L., et al. Chemokine receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus. Pediatr Res. 46:1999;82-84
57. Gambelunghe G., Ghaderi M., Brozzetti A., Del Sindaco P., Gharizadeh B., Nyren P., et al. Lack of association of CCR2-64I and CCR5-Δ32 with type 1 diabetes and latent autoimmune diabetes in adults. Hum Immunol. 64:2003;629-632
58. Benkirane M., Jin D.Y., Chun R.F., Koup R.A., Jeang K.T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem. 272:1997;30603-30606
59. Wu L., Paxton W.A., Kassam N., Ruffing N., Rottman J.B., Sullivan N., et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 185:1997;1681-1691
60. Landau N.R. HIV recent advances in AIDS research: genetics, molecular biology and immunology. Curr Opin Immunol. 11:1999;449-450
61. Dubois-Laforgue D., Hendel H., Caillat-Zucman S., Zagury J.F., Winkler C., Boitard C., et al. A common stromal cell-derived factor-1 chemokine gene variant is associated with early onset of type 1 diabetes. Diabetes. 50:2001;1211-1231
62. Satsangi J., Parkes M., Louis E., Hashimoto L., Kato N., Welsh K., et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet. 14:1996;199-202
63. Bokoch G.-M. Chemoattractant signalling and leukocyte activation. Blood. 86:1995;1649-1660
64. Sassy-Prigent C., Heudes D., Mandet C., Belair M.F., Michel O., Perdereau B., et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes. 49:2000;466-475
65. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 28:1997;1039-1057
66. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 15:1998;539-553
67. Parking H.H., Østerby R., Ritz B. Diabetic nephropathy. 6th ed. Brenner B.M. The kidney. vol. II:2000;1731-1773 W.B. Saunders, Philadelphia
68. Heesom A.E., Hibberd M.L., Millward A., Demaine A.G. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes. 46:1997;287-291
69. Tiwari J.L., Terasaki P.I. The data and statistical analysis. Tiwari J.L., Terasaki P.I. HLA and disease associations. 1985;18-27 Springer-Verlag, New York